Crolius Clayton 4
4 · DNA X, Inc. · Filed Feb 10, 2026
Research Summary
AI-generated summary of this filing
DNA X (SONM) CFO Crolius Clayton Receives 35,000 RSUs
What Happened
- Crolius Clayton, Chief Financial Officer of DNA X, Inc. (SONM), received a grant of 35,000 restricted stock units (RSUs) on February 9, 2026. The grant was recorded at $0.00 per unit (aggregate acquisition price $0).
- These RSUs are unvested compensation (not an open-market buy or sale) and represent the contingent right to receive one share per RSU when vested.
Key Details
- Transaction date and price: 2026-02-09; grant recorded at $0.00 per RSU.
- Shares/units reported after the transaction: beneficially owns 1,719 shares of common stock and 35,000 unvested RSUs (per filing footnote).
- Vesting: RSUs vest in equal monthly installments over one year following the grant date, subject to continued service (footnote F1).
- Reverse split note: reported amounts reflect a 1-for-18 reverse stock split effective Oct 27, 2025 (footnote F3).
- Filing timeliness: Form 4 was filed Feb 10, 2026 for the Feb 9 transaction (within the typical 2-business-day reporting window).
Context
- RSU grants are a common form of executive compensation and are not an immediate cash investment or sale; they convert to shares only as they vest. This award should be viewed as compensation, not a directional trade signal.
Insider Transaction Report
Form 4
DNA X, Inc.SONM
Crolius Clayton
Chief Financial Officer
Transactions
- Award
Common Stock
[F1][F2][F3]2026-02-09+35,000→ 36,719 total
Footnotes (3)
- [F1]Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.
- [F2]Consists of (i) 1,719 shares of common stock and (ii) 35,000 unvested restricted stock units.
- [F3]The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9.
Signature
/s/ Clay Crolius|2026-02-10